Investor Relations Adverum Biotechnologies is a clinical-stage company that aims to establish gene therapy as a new standard of care for a number of highly prevalent ocular diseases with the aspiration of developing functional cures for these diseases to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, ixoberogene soroparvovec (Ixo-vec), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. MORE ABOUT US Stock Quote NASDAQ: ADVM Contact Us We would love to hear from you. Please complete our contact form to engage with one of our team members. Press Releases Selecting the value will change the page content Financial Information Selecting the value will change the page content Select Year: Filter filing type: All Form Types Annual Filings Quarterly Filings Current Reports Proxy Filings Registration Statements Section 16 Filings Other Date Filing Type Filing Description Download / View Investors Investor Overview Corporate Governance Analyst Coverage Press Releases Sub Navigation Another Item Third Link Investor Events Webcasts Annual Reports Sub Navigation Annual Meetings Sub Navigation SEC Filings Sub Navigation Stock Information Print Page Email Alerts RSS Feed